22 March 2018

TIKOMED PRESENTS IBSOLVMIR AT BIO EUROPE

IBsolvMIR is TikoMed’s original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that occurs when transplanted cells enter the bloodstream and come in contact with blood. IBsolvMIR has been documented to be a very safe drug and has shown efficacy in a Phase 2 study. TikoMed will now focus efforts on partnering strategy in order to bring the drug to the market.
At BIO Europe, Adam Bruce, founder of TikoMed presented development status and partner strategy for the project.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
SEE MORE